Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

SAN DIEGO, April 5, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) recommended that the FDA approve Optimer's investigational antibiotic DIFICID™ (fidaxomicin) for the treatment of patients with Clostridium difficile infection (CDI), a bacterial infection in the lining of the gut that can cause severe diarrhea, colitis and in some cases death. In a unanimous 13-0 decision, the AIDAC found that the clinical evidence submitted by Optimer demonstrated the safety and effectiveness of DIFICID for the treatment of CDI.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"We view the vote of the FDA's panel of expert advisors, with diverse backgrounds ranging from infectious disease to biostatistics, as a strong endorsement for approving DIFICID for the treatment of CDI. We are encouraged that the advisory committee recognizes the urgent need for new treatment options for CDI and the seriousness of the increasing incidence of these infections," said Pedro Lichtinger, President and CEO of Optimer. "We are proud to be one step closer to providing patients, healthcare providers and physicians with a new treatment option for CDI, a serious and debilitating disease that can impact every aspect of a patient's life."

The FDA is not bound by the committee's guidance but takes its advice into consideration. Optimer submitted its New Drug Application (NDA) for DIFICID on November 30, 2010. The FDA accepted the DIFICID NDA filing and granted a six-month Priority Review in January 2011, assigning a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011.

"In Phase 3 clinical studies, DIFICID was proven to be as
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kansas blocked the sale of more ...
(Date:8/20/2014)... Aug. 20, 2014 PTC Therapeutics, Inc. (NASDAQ: ... upcoming investor conferences: - FBR 1 st ... Boston on Wednesday, September 3 rd ... Mandarin Oriental Boston on Thursday, September 4 th ... at the Bank of America Merrill Lynch Global Healthcare Conference ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... market research report is available in its ... Insurance in France, Key Trends and Opportunities ... Synopsis The report provides ... into the French personal accident and health ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2PTC Therapeutics to Participate at Upcoming Investor Conferences 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... its inception in 1999, Clongen Laboratories, a CLIA ... has focused on improving human health by refining ... research services for pharmaceutical, biotechnology, government, and academic ... Clongen Laboratories uses in their Clinical Diagnostics Division ...
... NARBERTH, Pa, Nov. 15, 2011 As any purchasing manager ... and shipping options is time lost. When purchasing surgical ... In January of 2010, Robert Edelstein, President of ... Day Saints Charities seeking a vendor for eye surgical ...
Cached Medicine Technology:Clongen Laboratories Announces Formation of Separate Clinical Diagnostics and Contract Research Divisions 2Millennium Surgical Corp. Provides Instruments to Latter Day Saints Charities for Humanitarian Projects 2
(Date:8/21/2014)... Sasha is a 10 year old Alaskan malamute, ... little older, and is having trouble getting up and down, ... have an owner who purchased a Butler Mobility Inclined Platform ... could no longer get up and down the stairs from ... She had tried a stair lift, but had to transfer ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The Onder ... and product liability law, announces the launch of a ... comprehensive information on morcellator surgery lawsuits for ... FDA morcellator cancer warning and the July 2014 morcellator ... the April 17, 2014 FDA warning on morcellator surgery ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... NJ. August 21, 2014. Researchers have published a ... outcomes of patients with motor complete spinal cord ... in functioning at discharge and follow-up among patients ... of print on August 2 by the ... 10.1016/j.apmr.2014.07.398). Findings included small but significant differences in ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
Breaking Medicine News(10 mins):Health News:Sasha Gets a Butler Mobility Inclined Platform Lift 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... often been associated with serious side-effects. Researchers at the ... mice, found a way of utilising the positive effects ... is acted on, current research at the Academy shows. ... PNAS (Proceedings of the National Academy of Sciences). ...
... bacterial DNA that often carries antibiotic resistance is a master ... widely differing bacterial species, shows a study made by ... with Chalmers University of Technology. The results are published in ... More and more bacteria are becoming resistant to our ...
... , MONDAY, April 11 (HealthDay News) -- Young mothers ... have children, and they also consume more saturated fat, ... Examining data from Project EAT (Eating and Activity ... of Minnesota focused on the link between parental status, ...
... Normal daily fluctuations in blood pressure aren,t linked with the ... heart attack or stroke in the morning, a new study ... who underwent three types of sleep/wake cycle experiments designed to ... daily rise and fall in blood pressure. In all ...
... pain can significantly reduce disability in older adults, according to ... newsletter from The Gerontological Society of America ... Annual Scientific Meeting in November 2010, the current WHAT,S HOT ... managing pain and preserving function, and methods to improve the ...
... , SUNDAY, April 10 (HealthDay News) -- Obese patients taking ... lost an average of 22 pounds over a year, while ... study has found. Qnexa is a combination of ... the United States, currently available under a variety of brand ...
Cached Medicine News:Health News:Antibiotic resistance spreads rapidly between bacteria 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 3Health News:Effective pain management crucial to older adults' well-being 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 3Health News:Experimental Weight-Loss Drug Seems to Work: Study 4
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
...
... White to buff-colored powder Activity: >=590g of gentamicin/mg (dry ... tests Limit of Methanol: Specific Rotation (25C): +107 ... H 2 O): 3.5 to 5.5 Loss on drying: ... : 25-50% C 2 + C 2a : ...
... Gentamycin sulfate is effective against gram ... as mycoplasma, by interfering with bacterial protein ... of ribosomes. Its suggested working concentration of ... and mammalian cells, thereby making a gentler ...
Medicine Products: